




DAMORA
THERAPEUTICS

Redefining care for people with blood disorders

Company Overview

May 2026



Disclaimers

The information contained in this presentation has been prepared by Damora Therapeutics Inc. and its affiliates (“Damora” or the “Company”) and contains information pertaining to the business and operations of the Company.

Forward-Looking Statements and Other Information

Certain information set forth in this presentation contains “forward-looking statements” within the meaning of applicable United States securities legislation. Except for statements of historical fact, certain information contained herein constitutes forward-looking statements which include but are not limited to statements regarding: our business strategy, including our ability to develop best-in-class therapeutics to address the full mutant CALR-driven myeloproliferative neoplasm disease spectrum that meaningfully improve both efficacy and convenience compared to INCA033989; the efficacy, safety profile, dosing regime, convenience, and tolerability of DMR-001; Damora’s ongoing and future clinical development activities, including the expected timing of Phase 1 clinical proof-of-concept data for DMR-001, and plans for and timing of investigational new drug applications for DMR-002 and DMR-003; estimated market sizes, potential growth opportunities, potential value creation and sample transactions; the length of time that the Company believes its existing cash resources will fund its operations, including expectations of cash runway; and management’s assessment of future plans and operations which are based on current internal expectations, estimates, projections, assumptions and beliefs, which may prove to be incorrect. Forward-looking statements can often be identified by the use of words such as “may”, “will”, “could”, “would”, “anticipate”, “believe”, “expect”, “intend”, “potential”, “estimate”, “scheduled”, “plans”, “planned”, “forecasts”, “goals” and similar expressions or the negatives thereof. Forward-looking statements are neither historical facts nor assurances of future performance. Forward-looking statements are based on a number of factors and assumptions made by management and considered reasonable at the time such information is provided, and forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements, including uncertainties and risks arising from regulatory feedback, including potential disagreement by regulatory authorities with our clinical trial design, interpretation of data and our ongoing or planned clinical trials for our product candidates; the expected or potential impact of macroeconomic conditions, including inflationary pressures, rising interest rates, general economic slowdown or a recession, changes in tariff/trade and monetary policy, volatile market conditions, financial institution instability, as well as geopolitical instability, including the ongoing military conflicts between Ukraine and Russia, conflicts in the Middle East, and geopolitical tensions between the United States and other countries, including China, on our operations; the implementation of changes in law, tariffs, sanctions, export or import controls, and other government measures that could impact our business operations, including restricting international trade by the United States, China or other countries and the BIOSECURE Act or similar act if passed into law; the impacts of adverse events or disappointing results in clinical trials of third parties, including our competitors developing product candidates that target similar mechanisms of action and/or indications as our product candidates; and those uncertainties and factors described under the heading “Risk Factors,” “Risk Factor Summary” and “Note about Forward-Looking Statements” in the Company’s most recent Annual Report on Form 10-K, as supplemented and updated by subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K that the Company has filed or will file with the SEC and the definitive proxy statement on DEF 14A that the Company filed with the SEC on December 31, 2025, as well as discussions of potential risks, uncertainties, and other filings by the Company from time to time, as well as risk factors associated with companies that operate in the biopharma industry, including those associated with the uncertainties of drug development. All of the forward-looking statements made in this presentation are qualified by these cautionary statements and other cautionary statements or other factors contained herein. Although management believes that the expectations conveyed by forward-looking statements herein are reasonable based on information available on the date such forward-looking statements are made, there can be no assurance that forward looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. The Company undertakes no obligation to update forward-looking statements if circumstances or management’s estimates or opinions should change except as required by applicable securities laws. The forward-looking statements contained herein are presented for the purposes of assisting readers in understanding the Company’s plan, objectives and goals and may not be appropriate for other purposes. The reader is cautioned not to place undue reliance on forward-looking statements.

Market and Industry Data

Certain information contained in this presentation and statements made orally during this presentation relate to or are based on studies, publications and other data obtained from third-party sources as well as our own internal estimates and research. While we believe these third-party sources to be reliable as of the date of this presentation, we have not independently verified, and make no representation as to the adequacy, fairness, accuracy or completeness of, any information obtained from third party sources. Forecasts and other forward-looking information obtained from these sources are subject to the same qualifications and uncertainties as the other forward-looking statements in this presentation. Statements as to our market and competitive position data are based on market data currently available to us, as well as management’s internal analyses and assumptions regarding the Company, which involve certain assumptions and estimates. These internal analyses have not been verified by any independent sources and there can be no assurance that the assumptions or estimates are accurate. While we are not aware of any misstatements regarding our industry data presented herein, our estimates involve risks and uncertainties and are subject to change based on various factors. As a result, we cannot guarantee the accuracy or completeness of such information contained in this presentation.

Damora Therapeutics: an emerging leader in blood disorders




DAMORA
THERAPEUTICS

NASDAQ: DMRA

- **Founded by Fairmount Funds Management** with a mission to fundamentally redefine care for patients with blood disorders
- **Portfolio of mutCALR-targeted therapies with best-in-class potential** for myeloproliferative neoplasms (MPNs), including essential thrombocythemia (ET) and myelofibrosis (MF)
- Corporate and R&D leadership with a **proven track record of clinical and commercial success**
- **Premier investor support, with ~\$533 million¹ in cash,** to accelerate lead asset DMR-001 through proof-of-concept and into registrational development

Rapidly advancing portfolio uniquely positioned to address the spectrum of patients across mutCALR-driven MPNs



DMR-001

Fc-null, extended half-life

Blocks mutCALR-driven oncogenic signaling, without engaging immune effector functions

First regulatory submission: mid-2026

DMR-003

T-cell engager

mutCALR x CD3 bi-specific recruits and directs T-cell-mediated killing of malignant cells

First regulatory submission: 2027

DMR-002

Fc-enhanced, extended half-life

Afucosylation enhances antibody-dependent cellular cytotoxicity and amplifies natural immune killing of malignant cells

First regulatory submission: 2H 2026

MPNs represent a spectrum of highly debilitating diseases

Essential Thrombocythemia (ET)

- High platelet counts **increase thrombosis and hemorrhage risk**
- Severe headaches, fatigue, mental fogginess, tingling in hands and feet, and other **symptoms negatively impact QoL**
- mutCALR patients are younger with **higher risk of transformation** to myelofibrosis
- **Available therapies do not treat underlying cause of disease** and have significant side effects (e.g., hydroxyurea)

Myelofibrosis (MF)

- Bone marrow fibrosis leads to **poor survival and high risk of transformation** to acute myeloid leukemia
- **Debilitating symptoms** include anemia, severe weakness and fatigue, splenomegaly, night sweats and bone pain
- **Available therapies do not treat underlying cause of disease** and largely only address symptoms


Significant need for highly effective, safe and convenient disease-modifying treatments

QoL, quality of life.

Sources: Tefferi 2025 (JAMA); Tefferi 2020 (Am J Hematol).

INCA'989 provided POC, with significant room for improvement

Less potent on Type 2 CALR mutations



Frequent, high-volume IV doses



Intravenous administration

Frequent dosing every two weeks

High-volume up to 2,500 mg

Different dose levels likely needed for Type 1 and Non-Type 1 patients, with dose escalation embedded in design of Phase 3 trial in ET

anti-mutCALR Fc-null antibody therapy was well-tolerated

INCA'989, INCA033989; IV, intravenous.

Sources: Klampfl 2013 (NEJM). Complete response defined as platelet count below 400x10⁹/L; bar graphs for Type 1 and Non-Type 1 generated based on swim plot. CALR mutation type breakdown representative of all mutCALR MPN patients. *Non-Type 1 mutations include Type 2 (32%) and Other (15%) CALR mutations. Other includes Type 1-like, Type 2-like and other uncategorized mutations.

DMR-001 has two ways to win: maximize efficacy and meaningfully improve the patient experience

Superior potency and exposure

Next-generation therapy **engineered to maximize efficacy across all CALR mutations** through superior potency and optimized exposure levels



- BROAD COVERAGE**
Targets both Type 1 & Type 2 mutations
- HIGH POTENCY**
Potential best-in-class affinity
- OPTIMIZED EXPOSURE**
Sustained therapeutic levels

Potential **best-in-class** disease modification in ET and MF

Improve patient experience

Differentiation through a **patient-centric design, maximizing the experience on multi-year therapy** with a potential first-to-market, simple, and quick autoinjector



- POTENTIAL FIRST TO MARKET**
Autoinjector format
- INFREQUENT SIMPLE ADMINISTRATION**
Quick, low-burden delivery
- LONG-TERM ADHERENCE**
Designed for chronic use

Potential **first-in-class** convenient solution for chronic therapy

Clinical development strategy is designed to generate rapid POC

Program	MoA	Stage		
		Discovery	IND-enabling	Clinical
DMR-001	Anti-mutCALR mAb (Fc-null, half-life extended)			Two POC readouts beginning mid-2027
DMR-002	Anti-mutCALR mAb (Fc-enhanced, half-life extended)			First regulatory submission expected 2H26
DMR-003	Anti-mutCALR x CD3 bsAb (T-cell engager)			First regulatory submission expected 2027

Large market opportunity, with ~25-35% of essential thrombocythemia & myelofibrosis driven by mutCALR

Assets designed by Paragon Therapeutics, with expertise in developing best-in-class biologics



DAMORA
THERAPEUTICS

Commercial opportunity

Multi- blockbuster potential in
mutCALR-driven MPNs



Current MPN treatments leave significant unmet need, with no disease-modifying therapeutics

ET patients are at **increased risk for thrombosis, hemorrhage, and conversion to MF**¹


60-70% of ET patients require **cytoreductive therapy** to reduce risk of thrombosis²

20-30% of patients receiving SOC cytoreductive therapies are **resistant** or **intolerant**³

>17% of mutCALR ET patients **transform to MF**⁴

There is need for highly safe, convenient, and targeted **disease-modifying** therapies

MF leads to **poor survival and significant risk of leukemia**, yet SOC largely addresses symptoms⁵



mutCALR targeted therapy presents an opportunity for much-needed **disease modification** that eradicates neoplasms

Notes: SOC: standard of care.

Sources: Internal KOL calls; ¹Campbell 2005 (Lancet); ²Loscocco 2024 (Blood); ³Hernandez-Boluda 2010 (Brit J Hem); ⁴Tefferi 2025 (JAMA); ⁵Gangat 2023 (Blood Cancer J).

Estimate >\$5B total addressable market for mutCALR-driven MPNs in the US alone



Essential thrombocythemia

~140,000 prevalent patients in the US

↳ ~25% have CALR driver mutations



Myelofibrosis

~20,000 prevalent patients in the US

↳ ~35% have CALR driver mutations

Estimate ~42,000 patients with mutCALR-driven MPNs in the US,
with majority indicated for cytoreductive / targeted treatment

Sources: Klampfl 2013 (NEJM); prevalence based on range from Mehta 2013 (Leukemia & Lymphoma), Shalis 2021 (Hematol Oncol Clin N Am), and Masarova 2025 (ASCO); Incyte 2025 Q2 report.
Incyte estimates a >\$7B US addressable market for anti-mutCALR therapy.

Significant initial opportunity plus high growth potential with expansion into lower-risk populations



Essential Thrombocythemia

~35K patients with mutCALR-driven ET in the US

~21K – 24.5K indicated for cytoreductive Tx

20% – 30% resistant or intolerant to SOC

~10.5K – 14K not indicated for cytoreductive Tx



Myelofibrosis

~7K patients with mutCALR-driven MF in the US

~4.8K – 5.5K with intermediate-to-high-risk MF

~1.4K – 2.1K with low-risk MF

~\$1.4B ruxolitinib US revenue *attributable to MF alone* in 2025

DMR-001 is competitively positioned to achieve significant market share on convenience alone

INCA'989 formatted for **in-clinic Q2W intravenous dosing**, with on-body injector in early development

Annual doses of anti-mutCALR

INCA'989
IV Q2W



INCA'989
OBI



DMR-001
SC Q4W+



KOLs view **SC dosing as required for wider adoption**, particularly in ET patients

"50% of patients would not accept IV treatment, whereas 20% would reject SC treatment. Every four weeks is meaningful for my patients."
– US KOL

"I would prescribe INCA033989 to all ET patients requiring cytoreduction if it was administered SC and half as many patients if IV."
– US KOL

"IV administration might be a barrier for [expansion into] low-risk ET patients."
– US KOL

DMR-001 is expected to be conveniently administered SC Q4W+ using an autoinjector



DAMORA
THERAPEUTICS

DMR-001


anti-mutCALR Fc-null antibody
lead program




CALR mutations drive constitutive JAK/STAT signaling and uncontrolled proliferation of myeloid progenitors in MPNs

mutCALR constitutively activates JAK/STAT signaling


Wild-type JAK/STAT signaling is driven by TPO binding to MPL



MutCALR activates MPL signaling independent of TPO



mutCALR drives uncontrolled proliferation and clonal advantage in the bone marrow




- Driver mutation (CALR, JAK2, MPL)
- Chromatin modification
- Tumor suppressor (ex: TP53)

Sources: Imai 2017 (Int J of Hem); Grabek 2020 (Cells).

INCA'989 demonstrated clinical POC in mutCALR-driven ET and MF

Essential Thrombocythemia


83.3% of patients achieved CHR at doses ≥ 400 mg, with 46.6% durable ≥ 12 weeks



Requires Q2W IV infusion with lower efficacy seen in Type 2 patients

Myelofibrosis

At week 24, 42% of patients achieved SVR25 and 33% achieved SVR35



Non-Type 1 patients underperform as seen by fewer patients hitting SVR25 and SVR35

SVR35 and SVR25, spleen volume reduction of 35% and 25%, respectively.

Sources: Mascarenhas 2025 (ASH). Notes: Durable complete hematologic response (CHR) defined as platelet count $< 400 \times 10^9/L$ and leukocytes $< 10 \times 10^9/L$ for ≥ 12 weeks.

DMR-001 is a potentially best-in-class anti-mutCALR mAb

Inhibits mutCALR-mediated proliferation with better *in vitro* potency than INCA'989

- **Demonstrated POC** for mechanism of action
- **Superior potency on Type 2 mutCALR**
- **Similar or better potency on Type 1 mutCALR**
- **Predicted equivalent safety** – does not bind to wild-type CALR

Subcutaneous formulation

- Targeting lower dose to enable convenient SC autoinjector format

Half-life extension through validated Fc modification

- **Longer exposure** to enhance sustained mutCALR inhibition and **reduce dosing frequency**

Effector-null human IgG1 Fc

Novel IP⁽¹⁾ for composition of matter into 2040s




DMR-001


⁽¹⁾ Damora has exercised its option to acquire certain intellectual property license rights pursuant to the antibody discovery and option agreement by and among Damora Therapeutics LLC, Paragon Therapeutics, Inc. and Paramora Holding LLC, dated October 7, 2025.

DMR-001 demonstrates higher binding affinity and ~3x potency improvement on Type 1 mutCALR compared to reference mAb

DMR-001 shows higher binding to Type 1




DMR-001 shows more potent inhibition of Type 1 mutCALR-dependent cell proliferation




Notes: MFI: mean fluorescence intensity. mutCALR-dependent cells are Ba/F3 cells expressing TpoR and mutCALR; Reference mutCALR mAb produced recombinantly based on US20230272055A1.

DMR-001 demonstrates higher binding affinity and ~10x potency improvement on Type 2 mutCALR compared to reference mAb

DMR-001 shows higher binding to Type 2




DMR-001 shows more potent inhibition of Type 2 mutCALR-dependent cell proliferation




DMR-001 expected to deliver highly efficacious exposure with convenient, infrequent SC dosing using conservative modeling

~5x longer half-life achieved for DMR-001 versus reference mutCALR mAb in NHPs



Dose required to match INCA'989 2500mg IV Q2W on C_{trough} would enable Q4W+ SC dosing for DMR-001



Plan to pursue convenient SC dose with less frequent administration to maximize convenience

SC, subcutaneous.

Notes: Reference mutCALR mAb produced recombinantly based on US20230272055A1. Day 42 Interim NHP PK Data after a single 30 mg/kg IV dose (n=4 per group). Bar chart reflects projections to match benchmark mAb 2500mg IV Q2W on C_{trough} and conservatively models 2x improvement in Type 2 potency in vivo.

Phase 1/1b trial designed to rapidly identify recommended dose and initiate expansion cohorts

First regulatory submission for DMR-001 planned in mid-2026 to enable initiation of global Phase 1/1b trial

Phase 1 dose escalation

- Dose escalation in combined ET and MF population
- Starting dose near anticipated therapeutic exposure
- Adaptive Bayesian design enabling enrichment
- *Generate data validating differentiated preclinical profile*


Phase 1b expansion

- Enroll distinct ET and MF population cohorts
- Explore combination approaches
- *Generate data on clinical response and durability*



***Target initiation of
Phase 3 development
as early as mid-2028***

Exceptional financial position to accelerate development through proof-of-concept and toward registration



Strong cash position with \$533M of cash and cash equivalents at the end of Q1 2026, with anticipated runway into 2029

Sources: Incyte public statements.

Notes: ROA: route of administration, MOA: mechanism of action, mAb: monoclonal antibody, bsAb: bispecific antibody, POC: proof-of-concept